Literature DB >> 23901221

Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy.

Camila Marques1, Francielli Licks, Ingrid Zattoni, Beatriz Borges, Luiz Eduardo Rizzo de Souza, Claudio Augusto Marroni, Norma Possa Marroni.   

Abstract

AIM: To investigate the effects of glutamine on oxidative/nitrosative stress and the vascular endothelial growth factor (VEGF)-Akt-endothelial nitric oxide synthase (eNOS) signaling pathway in an experimental model of portal hypertension induced by partial portal vein ligation (PPVL).
METHODS: Portal hypertension was induced by PPVL. The PPVL model consists of a partial obstruction of the portal vein, performed using a 20 G blunt needle as a guide, which is gently removed after the procedure. PPVL model was performed for 14 d beginning treatment with glutamine on the seventh day. On the fifteenth day, the mesenteric vein pressure was checked and the stomach was removed to test immunoreactivity and oxidative stress markers. We evaluated the expression and the immunoreactivity of proteins involved in the VEGF-Akt-eNOS pathway by Western blotting and immunohistochemical analysis. Oxidative stress was measured by quantification of the cytosolic concentration of thiobarbituric acid reactive substances (TBARS) as well as the levels of total glutathione (GSH), superoxide dismutase (SOD) activity, nitric oxide (NO) production and nitrotyrosine immunoreactivity.
RESULTS: All data are presented as the mean ± SE. The production of TBARS and NO was significantly increased in PPVL animals. A reduction of SOD activity was detected in PPVL + G group. In the immunohistochemical analyses of nitrotyrosine, Akt and eNOS, the PPVL group exhibited significant increases, whereas decreases were observed in the PPVL + G group, but no difference in VEGF was detected between these groups. Western blotting analysis detected increased expression of phosphatidylinositol-3-kinase (PI3K), P-Akt and eNOS in the PPVL group compared with the PPVL + G group, which was not observed for the expression of VEGF when comparing these groups. Glutamine administration markedly alleviated oxidative/nitrosative stress, normalized SOD activity, increased levels of total GSH and blocked NO overproduction as well as the formation of peroxynitrite.
CONCLUSION: Glutamine treatment demonstrated to reduce oxidative damage but does not reduce angiogenesis induced by PH in gastric tissue, demonstrating a beneficial role for the PI3K-Akt-eNOS pathway.

Entities:  

Keywords:  Glutamine; Oxidative stress; Partial portal vein ligation; Portal hypertension; Rats

Mesh:

Substances:

Year:  2013        PMID: 23901221      PMCID: PMC3725370          DOI: 10.3748/wjg.v19.i28.4464

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  55 in total

Review 1.  Hemodynamic alterations in liver cirrhosis.

Authors:  Giorgio La Villa; Paolo Gentilini
Journal:  Mol Aspects Med       Date:  2007-10-24

Review 2.  Measuring nitric oxide production in human clinical studies.

Authors:  D L Granger; N M Anstey; W C Miller; J B Weinberg
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Complications of cirrhosis.

Authors:  Robert S Rahimi; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

5.  Glutamine prevents gastric oxidative stress in an animal model of portal hypertension gastropathy.

Authors:  Camila Marques; José L Mauriz; Douglas Simonetto; Claudio A Marroni; María J Tuñon; Javier González-Gallego; Norma P Marrón
Journal:  Ann Hepatol       Date:  2011 Oct-Dec       Impact factor: 2.400

6.  Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats.

Authors:  Ming-Hung Tsai; Yasuko Iwakiri; Gregory Cadelina; William C Sessa; Roberto J Groszmann
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

Review 7.  Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis.

Authors:  J L Payen; P Calès; J J Voigt; S Barbe; C Pilette; L Dubuisson; H Desmorat; J P Vinel; A Kervran; J A Chayvialle
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

8.  Superoxide dismutase and glutathione in the gastric mucosa of patients with chronic liver disease.

Authors:  S Kikkawa; M Kadohara; H Kawasaki
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1992-12

Review 9.  Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?

Authors:  S Dimmeler; C Hermann; A M Zeiher
Journal:  Eur Cytokine Netw       Date:  1998-12       Impact factor: 2.737

10.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

Authors:  Mercedes Fernandez; Francesco Vizzutti; Juan Carlos Garcia-Pagan; Juan Rodes; Jaime Bosch
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  5 in total

1.  Synergistic antioxidant and anti-inflammatory action of N-acetylcysteine in portal hypertensive gastropathy in rats.

Authors:  Francielli Licks; Renata Minuzzo Hartmann; Elizângela Schemitt; Josieli Raskopf Colares; Camila Marques; Henrique Fillmann; Norma Possa Marroni
Journal:  Hepatol Forum       Date:  2022-04-26

2.  Glutamine Deprivation Causes Hydrogen Peroxide-induced Interleukin-8 Expression via Jak1/Stat3 Activation in Gastric Epithelial AGS Cells.

Authors:  Yun Mi Lee; Mi Jung Kim; Youngha Kim; Hyeyoung Kim
Journal:  J Cancer Prev       Date:  2015-09

3.  Blood Levels of Glutamine and Nitrotyrosine in Patients with Chronic Viral Hepatitis.

Authors:  Hussam Murad; Haythum Tayeb; Mahmoud Mosli; Misbahuddin Rafeeq; Mohammed Basheikh
Journal:  Int J Gen Med       Date:  2021-11-24

4.  Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension.

Authors:  Leon Adrian Muti; Alina Elena Pârvu; Alexandra M Crăciun; Nicolae Miron; Monica Acalovschi
Journal:  Clujul Med       Date:  2015-04-15

Review 5.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.